

# Jackson K Mukonzo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2669106/publications.pdf>

Version: 2024-02-01

33  
papers

703  
citations

623188

14  
h-index

552369

26  
g-index

36  
all docs

36  
docs citations

36  
times ranked

1172  
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 690-699.	1.1	124
2	Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 261.	1.3	79
3	Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes. <i>PLoS ONE</i> , 2014, 9, e86919.	1.1	61
4	Over-the-counter suboptimal dispensing of antibiotics in Uganda. <i>Journal of Multidisciplinary Healthcare</i> , 2013, 6, 303.	1.1	58
5	<i>In silico</i> prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 536-543.	1.1	44
6	A comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patients. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 77.	1.5	35
7	Medicinal plants used by traditional medicine practitioners to boost the immune system in people living with HIV/AIDS in Uganda. <i>European Journal of Integrative Medicine</i> , 2020, 35, 101011.	0.8	32
8	HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2011, 50, 531-540.	1.6	29
9	Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. <i>Clinical Infectious Diseases</i> , 2018, 67, 785-790.	2.9	25
10	Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperazine in the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Sub-Saharan Africa: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0264339.	1.1	23
11	Genetic Variations in ABCB1 and CYP3A5 as well as Sex Influence Quinine Disposition Among Ugandans. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 346-352.	1.0	20
12	Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals. <i>International Journal of Infectious Diseases</i> , 2019, 83, 98-101.	1.5	20
13	CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure. <i>Pharmacogenomics</i> , 2014, 15, 1423-1435.	0.6	17
14	Characterizing plasma albumin concentration changes in TB/HIV patients on anti retroviral and anti-tuberculosis therapy. <i>In Silico Pharmacology</i> , 2014, 2, 3.	1.8	16
15	CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. <i>Pharmacogenomics</i> , 2016, 17, 603-613.	0.6	15
16	Tips for charting the course of a successful health research career. <i>Journal of Multidisciplinary Healthcare</i> , 2013, 6, 163.	1.1	14
17	Field-adapted sampling of whole blood to determine the levels of amodiaquine and its metabolite in children with uncomplicated malaria treated with amodiaquine plus artesunate combination. <i>Malaria Journal</i> , 2009, 8, 52.	0.8	12
18	Trimester-Specific Population Pharmacokinetics and Other Correlates of Variability in Sulphadoxine-Pyrimethamine Disposition Among Ugandan Pregnant Women. <i>Drugs in R and D</i> , 2015, 15, 351-362.	1.1	12

#	ARTICLE	IF	CITATIONS
19	Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TBâ€“rifampicin sensitivity among Ugandan patients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 114, 107-114.	0.7	12
20	Poor immunological recovery among severely immunosuppressed antiretroviral therapy-naïve Ugandans. HIV/AIDS - Research and Palliative Care, 2013, 5, 309.	0.4	9
21	Data on medicinal plants used by herbalists for boosting immunity in people living with HIV/AIDS in Uganda. Data in Brief, 2020, 29, 105097.	0.5	9
22	Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy. Journal of Clinical Pharmacology, 2015, 55, 1229-1235.	1.0	8
23	The challenge of paediatric efavirenz dosing. Aids, 2014, 28, 1855-1857.	1.0	6
24	Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study. Journal of Personalized Medicine, 2021, 11, 1303.	1.1	6
25	Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study. Pathogens, 2019, 8, 161.	1.2	4
26	CIHR canadian HIV trials network HIV workshop: ethical research through community participation and strengthening scientific validity. Pan African Medical Journal, 2014, 19, 44.	0.3	3
27	Transition modeling of neuropsychiatric impairment in HIV. Computers in Biology and Medicine, 2016, 73, 141-146.	3.9	3
28	Pharmacovigilance of suspected or confirmed therapeutic ineffectiveness of artemisinin-based combination therapy: extent, associated factors, challenges and solutions to reporting. Malaria Journal, 2020, 19, 389.	0.8	2
29	Antiretroviral drugs found in pork on Ugandan market: Implications for HIV/AIDS treatment. One Health, 2020, 9, 100125.	1.5	2
30	Healthcare professionalsâ€™ perspective can guide post-marketing surveillance of artemisinin-based combination therapy in Uganda. Malaria Journal, 2020, 19, 63.	0.8	2
31	Maximizing Knowledge Extraction From Patientâ€“Reported Outcome Data Using Exposureâ€“Outcome Item Response Modeling Approach: Understanding Efavirenzâ€“Induced Central Nervous System Toxicity. Journal of Clinical Pharmacology, 2020, 60, 711-721.	1.0	1
32	Output from the CIHR Canadian HIV Trials Network international postdoctoral fellowship for capacity building in HIV clinical trials. HIV/AIDS - Research and Palliative Care, 2018, Volume 10, 151-155.	0.4	0
33	Application of the anatomical chemical system/defined daily doses: Challenges and way forward for resourceâ€“limited countries. Journal of Clinical Pharmacy and Therapeutics, 2021, , .	0.7	0